Literature DB >> 1932909

High potency factor VIII concentrates: value not proved?

J D Cash1.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1932909      PMCID: PMC1671083          DOI: 10.1136/bmj.303.6803.633

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Supply of blood products.

Authors:  J D Cash
Journal:  BMJ       Date:  1991-04-06

2.  Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII.

Authors:  J B Montoro; S Rodríguez; C Altisent; J M Tusell
Journal:  Lancet       Date:  1991-05-18       Impact factor: 79.321

3.  Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate.

Authors:  C M Kessler; K Sachse
Journal:  Lancet       Date:  1990-06-09       Impact factor: 79.321

4.  Inhibitors to monoclonal antibody purified factor VIII.

Authors:  B A Bell; E M Kurczynski; G Bergman
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

5.  Coagulation factor VIII concentrates and the marketplace.

Authors:  J D Cash
Journal:  Lancet       Date:  1988-06-04       Impact factor: 79.321

6.  A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.

Authors:  T Burnouf; M Burnouf-Radosevich; J J Huart; M Goudemand
Journal:  Vox Sang       Date:  1991       Impact factor: 2.144

  6 in total
  3 in total

1.  High purity factor VIII concentrates and HIV infection.

Authors:  C A Lee
Journal:  BMJ       Date:  1992-03-07

2.  High potency factor VIII concentrates.

Authors:  E E Mayne
Journal:  BMJ       Date:  1992-02-01

3.  High potency factor VIII concentrates.

Authors: 
Journal:  BMJ       Date:  1991-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.